tbuckley/cabot-search huggingface dataset:
A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Authors: H. Arasanz, M. Zuazo, M Martínez Aguillo, B Hernández Marín, G. Fernández-Hinojal, A.I. Bocanegra, I Morilla Ruiz, M. Gato-Cañas, L. Teijeira, P. Sala, M.J. García-Granda, R. Vera, G. Kochan, D. Escors
Journal: Annals of Oncology (2019)
EMR achieves similar oncological outcomes as ESD for gastric neoplasia of &lt;1cm, requiring less expertise, training and time
Authors: Matthew Banks, Noriya Uedo, Pradeep Bhandari, Takuji Gotoda
Journal: Gut (2019)

We thank Drs Shahidi and Bourke1 for their kind interest in our British Society of Gastroenterology guidelines.2 

They present a valid argument that endoscopic mucosal resection (EMR) rather than endoscopic submucosal dissection (ESD) should be the first-line therapy for all gastric neoplasia, irrespective of lesion size, location or histopathology, citing supportive evidence from the Japan Gastroenterological Endoscopy Society (JGES)3 and the European Society of Gastrointestinal Endoscopy (ESGE),4 and three systematic reviews.5–7 We accept the compelling, although low-quality evidence from the systematic reviews demonstrating that en bloc resection, R0 resection and recurrence rates favoured ESD overall.

Although the JGES guidelines state that ESD is better than EMR, they provide the caveat that there have been no randomised controlled trials examining the therapeutic results between EMR and ESD in …
Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis
Authors: B. Bonardi, M. Bruzzone, O. Goldrat, L.l. De Mastro, P. Anserini, C. Massarotti, G. Mangili, M. Ceppi, I. Demeestere, M. Lambertini
Journal: Annals of Oncology (2019)
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis
Authors: C. Dutriaux, C. Robert, J.J. Grob, L. Mortier, O. Dereure, C. Lebbe, S. Mansard, F. Grange, E.-M. Neidhardt, T. Lesimple, L. Machet, C. Bedane, H. Maillard, S. Dalac-Rat, C. Nardin, A. Szenik, A. Denden, P. Saiag
Journal: Annals of Oncology (2019)
The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
Authors: W. Ichikawa, M. Takeuchi, Y. Sunakawa, K. Shitara, K. Oba, Y. Yamada, W. Koizumi, Y. Sakata, H. Furukawa, M. Takeuchi, M. Fujii
Journal: Annals of Oncology (2019)
Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm
Authors: Jean-Baptiste Lascarrou, Hamid Merdji, Amélie Le Gouge, Gwenhael Colin, Guillaume Grillet, Patrick Girardie, Elisabeth Coupez, Pierre-François Dequin, Alain Cariou, Thierry Boulain, Noelle Brule, Jean-Pierre Frat, Pierre Asfar, Nicolas Pichon, Mickael Landais, Gaëtan Plantefeve, Jean-Pierre Quenot, Jean-Charles Chakarian, Michel Sirodot, Stéphane Legriel, Julien Letheulle, Didier Thevenin, Arnaud Desachy, Arnaud Delahaye, Vlad Botoc, Sylvie Vimeux, Frederic Martino, Bruno Giraudeau, Jean Reignier
Journal: New England Journal of Medicine (2019)

Moderate therapeutic hypothermia is currently recommended to improve neurologic outcomes in adults with persistent coma after resuscitated out-of-hospital cardiac arrest. However, the effectiveness of moderate therapeutic hypothermia in patients with nonshockable rhythms (asystole or pulseless electrical activity) is debated.
Genomic landscape of primary malignant melanoma of esophagus
Authors: J. Dai, L. Si, C. Cui, X. Sheng, Y. Kong, Z. Chi, L. Mao, X. Wang, B. Lian, S. Li, X. Yan, B. Tang, X. Bai, L. Zhou, J. Guo
Journal: Annals of Oncology (2019)
Global Prevalence of Hypertension in Children
Authors: Peige Song, Yan Zhang, Jinyue Yu, Mingming Zha, Yajie Zhu, Kazem Rahimi, Igor Rudan
Journal: JAMA Pediatrics (2019)

Reliable estimates of the prevalence of childhood hypertension serve as the basis for adequate prevention and treatment. However, the prevalence of childhood hypertension has rarely been synthesized at the global level.To conduct a systematic review and meta-analysis to assess the prevalence of hypertension in the general pediatric population.PubMed, MEDLINE, Embase, Global Health, and Global Health Library were searched from inception until June 2018, using search terms related to hypertension (hypertension OR high blood pressure OR elevated blood pressure), children (children OR adolescents), and prevalence (prevalence OR epidemiology).Studies that were conducted in the general pediatric population and quantified the prevalence of childhood hypertension were eligible. Included studies had blood pressure measurements from at least 3 separate occasions.Two authors independently extracted data. Random-effects meta-analysis was used to derive the pooled prevalence. Variations in the prevalence estimates in different subgroups, including age group, sex, setting, device, investigation period, BMI group, World Health Organization region and World Bank region, were examined by subgroup meta-analysis. Meta-regression was used to establish the age-specific prevalence of childhood hypertension and to assess its secular trend.Prevalence of childhood hypertension overall and by subgroup.A total of 47 articles were included in the meta-analysis. The pooled prevalence was 4.00% (95% CI, 3.29%-4.78%) for hypertension, 9.67% (95% CI, 7.26%-12.38%) for prehypertension, 4.00% (95% CI, 2.10%-6.48%) for stage 1 hypertension, and 0.95% (95% CI, 0.48%-1.57%) for stage 2 hypertension in children 19 years and younger. In subgroup meta-analyses, the prevalence of childhood hypertension was higher when measured by aneroid sphygmomanometer (7.23% vs 4.59% by mercury sphygmomanometer vs 2.94% by oscillometric sphygmomanometer) and among overweight and obese children (15.27% and 4.99% vs 1.90% among normal-weight children). A trend of increasing prevalence of childhood hypertension was observed during the past 2 decades, with a relative increasing rate of 75% to 79% from 2000 to 2015. In 2015, the prevalence of hypertension ranged from 4.32% (95% CI, 2.79%-6.63%) among children aged 6 years to 3.28% (95% CI, 2.25%-4.77%) among those aged 19 years and peaked at 7.89% (95% CI, 5.75%-10.75%) among those aged 14 years.This study provides a global estimation of childhood hypertension prevalence based on blood pressure measurements in at least 3 separate visits. More high-quality epidemiologic investigations on childhood hypertension are still needed.
Crossed looks on lung cancer perception and knowledge from general public and physicians in France: Results of a two-fold survey
Authors: C. Mascaux, S. Sauvajeon, J. Cadranel, C. Chouaid, J.B. Stern, A. Vergnenegre, C. Cortot, L. Guery, K. Belkhiria, I. De la Porte, M. Urbieta, M. Perol
Journal: Annals of Oncology (2019)
Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy
Authors: S.A. Jacobs, H. Sethi, T. Kolveska, T.J. George, S. Shchegrova, T. Tin, J. Lee, A. Olson, D. Renner, E. Kalashnikova, G. Yothers, N. Wolmark, K.L. Pogue-Geile, A. Srinivasan, J. Kortmansky, M. Louie, R. Salari, B. Zimmermann, A. Aleshin, C.J. Allegra
Journal: Annals of Oncology (2019)
Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA)
Authors: N.S. Ijzerman, C. Drabbe, D. Den Hollander, M. Mohammadi, H. van Boven, I.M.E. Desar, H. Gelderblom, D.J. Grünhagen, A.K.L. Reyners, R.H.J. Mathijssen, N. Steeghs, W.T.A. van der Graaf
Journal: Annals of Oncology (2019)
Polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib
Authors: A. Zeidan, P. Becker, P. Patel, G. Schiller, M.L. Tsai, T. Lin, E. Wang, M. Erlander, J. Cortes
Journal: Annals of Oncology (2019)
Abstract 16699: Deformation Patterns Differ in Genotype-Positive Patients with Hypertrophic Cardiomyopathy
Authors: Jeffrey B Geske, Johan M Bos, Bernard J Gersh, Steve R Ommen, Ben Eidem, Michael J Ackerman
Journal: Circulation (2012)

Objective: Echocardiographic strain imaging with 2-dimensional speckle tracking is an emerging tool for defining cardiac function and pre-clinical cardiac hypertrophy. In hypertrophic cardiomyopath...
Abstract 13237: Thioredoxin Interacting Protein Promotes Endothelial Cell Inflammation in Response to Disturbed Flow by Repressing Kruppel-Like Factor 2
Authors: Xiaoqun Wang, Patrizia Nigro, Keigi Fujiwara, Amy Mohan, Christine Christie, Chen Yan, Bradford C Berk
Journal: Circulation (2011)

Background: Endothelial cells (EC) at regions exposed to disturbed flow (d-flow), such as lesser curvature of aortic arch and branch points of outflow tracts, are more susceptible to inflammation a...
Minimal invasive microscopic tooth preparation in esthetic restoration: a specialist consensus
Authors: Haiyang Yu, Yuwei Zhao, Junying Li, Tian Luo, Jing Gao, Hongchen Liu, Weicai Liu, Feng Liu, Ke Zhao, Fei Liu, Chufan Ma, Juergen M. Setz, Shanshan Liang, Lin Fan, Shanshan Gao, Zhuoli Zhu, Jiefei Shen, Jian Wang, Zhimin Zhu, Xuedong Zhou
Journal: International Journal of Oral Science (2019)

By removing a part of the structure, the tooth preparation provides restorative space, bonding surface, and finish line for various restorations on abutment. Preparation technique plays critical role in achieving the optimal result of tooth preparation. With successful application of microscope in endodontics for >30 years, there is a full expectation of microscopic dentistry. However, as relatively little progress has been made in the application of microscopic dentistry in prosthodontics, the following assumptions have been proposed: Is it suitable to choose the tooth preparation technique under the naked eye in the microscopic vision? Is there a more accurate preparation technology intended for the microscope? To obtain long-term stable therapeutic effects, is it much easier to achieve maximum tooth preservation and retinal protection and maintain periodontal tissue and oral function health under microscopic vision? Whether the microscopic prosthodontics is a gimmick or a breakthrough in obtaining an ideal tooth preparation should be resolved in microscopic tooth preparation. This article attempts to illustrate the concept, core elements, and indications of microscopic minimally invasive tooth preparation, physiological basis of dental pulp, periodontium and functions involved in tool preparation, position ergonomics and visual basis for dentists, comparison of tooth preparation by naked eyes and a microscope, and comparison of different designs of microscopic minimally invasive tooth preparation techniques. Furthermore, a clinical protocol for microscopic minimally invasive tooth preparation based on target restorative space guide plate has been put forward and new insights on the quantity and shape of microscopic minimally invasive tooth preparation has been provided.
EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Authors: N. Penel, J.-Y. Blay, J. Wallet, A. Le Cesne, A. Italiano, O. Mir, S. Taieb, M. Vanseymortier, P. Desmet, E. Decoupigny, J. Courtial, M.C. Le Deley
Journal: Annals of Oncology (2019)
Stroke Risk as a Function of Atrial Fibrillation Duration and CHA <sub>2</sub> DS <sub>2</sub> -VASc Score
Authors: Rachel M. Kaplan, Jodi Koehler, Paul D. Ziegler, Shantanu Sarkar, Steven Zweibel, Rod S. Passman
Journal: Circulation (2019)

Studies of patients with cardiovascular implantable electronic devices show a relationship between atrial fibrillation (AF) duration and stroke risk, although the interaction with CHA2DS2-VASc score is poorly defined. The objective of this study is to evaluate rates of stroke and systemic embolism (SSE) in patients with cardiovascular implantable electronic devices as a function of both CHA2DS2-VASc score and AF duration.Data from the Optum electronic health record deidentified database (2007-2017) were linked to the Medtronic CareLink database of cardiovascular implantable electronic devices capable of continuous AF monitoring. An index date was assigned as the later of either 6 months after device implantation or 1 year after electronic health record data availability. CHA2DS2-VASc score was assessed using electronic health record data before the index date. Maximum daily AF burden (no AF, 6 minutes-23.5 hours, and >23.5 hours) was assessed over the 6 months before the index date. SSE rates were computed after the index date.Among 21 768 nonanticoagulated patients with cardiovascular implantable electronic devices (age, 68.6±12.7 years; 63% male), both increasing AF duration (P<0.001) and increasing CHA2DS2-VASc score (P<0.001) were significantly associated with annualized risk of SSE. SSE rates were low in patients with a CHA2DS2-VASc score of 0 to 1 regardless of device-detected AF duration. However, stroke risk crossed an actionable threshold defined as >1%/y in patients with a CHA2DS2-VASc score of 2 with >23.5 hours of AF, those with a CHA2DS2-VASc score of 3 to 4 with >6 minutes of AF, and patients with a CHA2DS2-VASc score ≥5 even with no AF.There is an interaction between AF duration and CHA2DS2-VASc score that can further risk-stratify patients with AF for SSE and may be useful in guiding anticoagulation therapy.
History of Medicine in Ireland
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial
Authors: Martin G. Sauer, Peter J. Lang, Michael H. Albert, Peter Bader, Ursula Creutzig, Matthias Eyrich, Johann Greil, Bernd Gruhn, Wolfgang Holter, Thomas Klingebiel, Bernhard Kremens, Heiko von der Leyen, Christine Mauz-Körholz, Roland Meisel, Kirsten Mischke, Ingo Müller, Charlotte M. Niemeyer, Christina Peters, Christine Pohler, Dirk Reinhardt, Birgit Burkhardt, Paul G. Schlegel, Ansgar S. Schulz, Johanna Schrum, Petr Sedlacek, Brigitte Strahm, Wilhelm Woessmann, Rupert Handgretinger, Martin Zimmermann, Arndt Borkhardt
Journal: Leukemia (2019)
PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma
Authors: H. Chae, J.E. Kim, W. Kim, J.-S. Lee, S.Y. Song, M.H. Lee, H.W. Chung, J.S. Song, J.-H. Ahn
Journal: Annals of Oncology (2019)
Doctor in Appalachian pill mill case is sentenced to 40 years in prison
Authors: Owen Dyer
Journal: BMJ (2019)

A doctor accused of running a “pill mill” has been sentenced to 40 years’ imprisonment by a federal court in Virginia.

Joel Smithers, 36, was convicted of 859 counts of illegally distributing opioids, one count of possession with the intent to illegally distribute, and one count of maintaining a place for that purpose.

The jury also found that oxycodone and oxymorphone that Smithers prescribed to a woman from West Virginia caused her death.

Smithers prescribed more than 500 000 opioid doses, taking only cash or credit card and refusing to accept insurance, the court heard. He made about $700 000 (£570 000; €640 000) in …
ASN002 证明有疗效并可改善AD 炎症
Authors: R. Bissonnette, C. Maari, S. Forman, N. Bhatia, M. Lee, J. Fowler, S. Tyring, D. Pariser, H. Sofen, S. Dhawan, M. Zook, D.J. Zammit, H. Usansky, L. Denis, N. Rao, T. Song, A.B. Pavel, E. Guttman‐Yassky
Journal: British Journal of Dermatology (2019)

可用于治疗中度至重度特应性湿疹的药物很少。ASN002是一种新型口服(经口服用)药物,试验表明其可降低各种在皮肤炎症中产生作用的蛋白的活性。在当前研究中,在中度至重度湿疹患者中评估了每天一次持续4 周给药的不同剂量 ASN002 的安全性和疗效,并与安慰剂进行了比较。安慰剂是由与用于制造 ASN002 的基材相同的材料制成的药片,但不含有任何活性药物。共计 27 名患者接受 ASN002 治疗,9 名患者接受安慰剂治疗。通常,ASN002耐药良好,而且引起的副作用有限,更高剂量的 ASN002 未使副作用的频率或严重程度增加。经过 4 周治疗后,接受 ASN002 治疗的患者相比接受安慰剂治疗的患者,其湿疹的严重程度得到更好的改善,而且这些正面效应早在开始治疗后 2 周便已显现。另外,ASN002 治疗还可快速改善瘙痒程度,而且可能导致与炎症相关的血液循环蛋白的水平显著降低。总而言之,令人鼓舞的 ASN002 疗效和安全性特征使得有必要在中度至重度湿疹患者中进一步研究 ASN002。
Landmark perspective: Acute radiation syndrome
Authors: S. C. Finch
Journal: JAMA (1987)

THE ATOMIC bomb detonations of Hiroshima and Nagasaki in 1945 abruptly awakened the world to the realities of the nuclear age. Radiologists, radiation physicists, and some physicians were aware of the sickness that frequently accompanied the use of x-ray therapy, but few knew the constellation of devastating events that may occur after whole-body exposure to excessive amounts of ionizing radiation. Although the majority of acute deaths in Hiroshima and Nagasaki were due to burns and other forms of physical trauma, at least a third of the victims probably died of radiation sickness, with many more developing varying degrees of acute systemic illness secondary to radiation exposure. The Japanese quickly recognized the peculiar effects that resulted from atomic bomb exposure, but not until observations were reported in the medical literature by several astute American military physicians did the acute radiation syndrome become known throughout the scientific world. The LANDMARK ARTICLE by
National Gonorrhea Therapy Monitoring Study
Authors: Richard E. Kaufman, Robert E. Johnson, Harold W. Jaffe, Clyde Thornsberry, Gladys H. Reynolds, Paul J. Wiesner
Journal: New England Journal of Medicine (1976)

To monitor the efficacy of the 1972 United States Public Health Service recommended treatment regimens for uncomplicated gonorrhea, we studied 9008 patients who were randomly assigned either to aqueous procaine penicillin G, 4.8 million units intramuscularly plus 1 g of oral probenecid, or to one of the three other recommended regimens. Among the 3871 patients re-examined within three to seven days after therapy, the penicillin-probenecid regimen was successful in 96.8 per cent, whereas the cure rates of the ampicillin-probenecid, tetracycline, and spectinomycin regimens were 92.8, 96.2, and 94.8 per cent, respectively. In clinics comparing the regimens, penicillin G-probenecid was as effective as tetracycline, but more effective than ampicillin-probenecid (P less than 0.05) and spectinomycin (P less than 0.01). However, in patients re-examined three to 14 days after treatment, only the ampicillin-probenecid regimen was significantly less effective than penicillin probenecid (P less than 0.01). Despite these differences in results, all four regimens recommended by the Public Health Service provided effective therapy for uncomplicated gonorrhea.
Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC)
Authors: A. Necchi, R. Madison, J. Chung, D. Raggi, A. Briganti, F. Montorsi, J.L. Boormans, Y. Liu, J.J. De Jong, J. Chung, P.C. Black, J.S. Ross, S.M. Ali, E. Davicioni, E.A. Gibb
Journal: Annals of Oncology (2019)
Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Authors: T.K. Choueiri, J. Kocsis, R.K. Pachynski, A. Poprach, M. Deshazo, Y. Zakharia, P.N. Lara, S.K. Pal, L. Geczi, T.H. Ho, L. Mangel, B. Redman, C.W. Ryan, T. Olencki, B.E. Simpson, B. Adams, L. Robertson, M. Darif, C. Theuer, N. Agarwal
Journal: Annals of Oncology (2019)
Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study
Authors: Edward Burn, James Weaver, Daniel Morales, Albert Prats-Uribe, Antonella Delmestri, Victoria Y Strauss, Ying He, Danielle E Robinson, Rafael Pinedo-Villanueva, Spyros Kolovos, Talita Duarte-Salles, William Sproviero, Dahai Yu, Michel Van Speybroeck, Ross Williams, Luis H John, Nigel Hughes, Anthony G Sena, Ruth Costello, Belay Birlie, David Culliford, Caroline O'Leary, Henry Morgan, Theresa Burkard, Daniel Prieto-Alhambra, Patrick Ryan
Journal: The Lancet Rheumatology (2019)
Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer
Authors: L.S. Rasmussen, M. Yilmaz, U.G. Falkmer, L Ø Poulsen, S.E. Bojesen, B. Vittrup Jensen, A.Z. Johansen, I.M. Chen, C.P. Hansen, J.P. Hasselby, P. Pfeiffer, J.K. Bjerregaard, S.E. Nielsen, F.Z. Andersen, N.H. Holländer, M. Bøgsted, J.S. Johansen
Journal: Annals of Oncology (2019)
Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: Long-term survival and toxicity analysis
Authors: None Sekine, H. Harada, N. Yamamoto, M. Wakabayashi, H. Murakami, K. Goto, N. Nogami, T. Seto, F. Oshita, H. Okamoto, H. Tanaka, T. Tamura, S. Ishikura, Y. Ohe
Journal: Annals of Oncology (2019)